                </a></li></ul></div><p><strong>Figure 7.  <span>Protease Inhibitor-Resistant HIV-1 has Impaired CA-SP1 Cleavage.</span></strong></p><a id="article1.body1.sec3.sec5.fig1.caption1.p1" name="article1.body1.sec3.sec5.fig1.caption1.p1"></a><p>Wild-type NL4-3 and protease mutant NL4-3 PR<sub>I54V+V82A</sub> virions were collected from transfected 293T cells grown in the presence (20 ÂµM) or absence of bevirimat and analyzed for particle maturation by Western blot using a p24 monoclonal antibody. The protease mutant is deficient in CA-SP1 cleavage and is comparable to bevirimat-treated wild-type virus, however, the drug has a more dramatic effect on CA-SP1 cleavage in HIV-1 PR<sub>I54V+V82A</sub>.</p>
